physicians

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five

Over the past several weeks, we’ve talked about how collaborations among key opinion leaders, clinical investigators and pharmaceutical and biotechnology companies benefit the companies, the KOLs or clinical investigators, and patients. The foundation of these mutually-beneficial collaborations is the objective, methodical approach to understanding KOLs’ and clinical investigators’ skills and experiences. Many methods promise to …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One

Now more than ever, pharmaceutical companies’ relationships with physician thought leaders, also known as key opinion leaders (KOLs), are under intense scrutiny. Industry ethicists and watchdogs alike have speculated on the objectivity of medical education presentations and other aspects of KOL involvement during the marketing of new drug therapies. However, the truth is that physician …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One Read More »